DermiPsor Set for Phase III Clinical Trial

Meytag Technology Incubator portfolio company DermiPsor Ltd. will begin Phase III clinical trials of its psoriasis cream after it was found to be safe and more effective than placebos in Phase II trials. The Phase II trial included 168 patients at five medical centers in the US. All patients were treated with DermiPsor’s psoriasis cream on one side of their bodies and with a placebo on the other in order to conduct a comparative study. Neither the patients nor their doctors knew which cream was applied on which side.